Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in the frontline setting, by offering effective, targeted therapy that provides significant clinical benefits and improves overall survival compared with traditional chemotherapy.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP: 5.Future Directions and Research Priorities in BTKi Treatment Approaches

EP: 6.Latest Trends and Innovations in CLL and MCL Treatment

EP: 7.CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 8.Navigating CLL Treatment Choices

EP: 9.Therapy Sequencing in CLL

EP: 10.MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 11.MCL Therapy Selection and Sequencing

EP: 12.Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL

EP: 13.Latest ASH Updates: Clinical Use of BTK Inhibitors in Management of CLL and MCL

Now Viewing

EP: 14.Impact of BTK Inhibitors on Treatment Paradigm of CLL and MCL

EP: 15.Patient-Centered Selection of BTK Inhibitors: Balancing Clinical Factors and Patient Preferences

EP: 16.Implementation of Shared Decision-Making in BTK Inhibitor Treatment

EP: 17.Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence

EP: 18.Future Directions and Overcoming Challenges in BTK Inhibitor Therapy

EP: 19.Impact of Access Challenges on Patient Outcomes in CLL and MCL Care

EP: 20.Balancing Clinical Benefits and Costs of BTK Inhibitors

EP: 21.Inflation Reduction Act: Impact on Health Care Systems’ Utilization of BTK Inhibitors

EP: 22.Inflation Reduction Act: Impact on Affordability of BTK Inhibitors

1. How have BTK inhibitors transformed the treatment paradigm for patients with CLL and MCL, particularly in the frontline setting?

Related Videos